Mike Flanagan
Chief Scientific & Technology Officer Avidity Biosciences
Seminars
Tuesday 4th November 2025
Spotlighting Emerging Clinical Profiles of AOCs for Precision Therapy Applications in Muscle & Cardiac Diseases
11:00 am
• Understanding AOC novel therapeutic approach for targeted oligonucleotide delivery to skeletal and cardiac tissues
• Showcasing early clinical promise of AOCs in treating rare muscle diseases like DM1, FSHD, and DMD
• Explaining AOC platform extension to precision cardiology, expanding the potential of oligonucleotide based therapies
